Abstract:Background: Increased HBV-replication and/or intracellular HBsAgretention favor the onset of hepatocellular-carcinoma (HCC).Here, we define mutations in pre-S1/Pre-S2/S-gene correlated with HBVinduced HCC in-vivo, and investigate their impact on HBsAgretention and secretion in an in-vitro model.Methods: Sixty-seven HBV chronically-infected patients (74.6% genotype-D; 20.9% genotype-A; and 4.5% others), 19 of them with HCC and 48 asymptomatic patients (as control), were analyzed.Association of mutations with HCC was assessed by Fisher-test with Benjamini-Hochberg for multiple-comparison correction.Mutants were constructed by site-directed mutagenesis and expressed in HuH7-hepatocytes using the expression-vectors pCHD9 with fulllength HBV-genome (for mutations S98T S1 -P203Q S -S210R S ) and pCHsAgD with pre-S1/pre-S2/S-gene (for N40I S -K141N S ).After 72h quantitative-HBsAg was tested in cell-supernatants and in celllysates using Abbott-Architect assay.Results: Novel mutations in pre-S1 (S98T S1 ), and S region (N40I S -K141N S -P203Q S -S210R S ) correlate with HCC (P = 10 -2 to 10 -4 ) invivo.19/19 patients with HCC carry ≥1 of them (range-prevalence: 12.5% to 37.5%), while these mutations are absent (0/48 for N40I S ) or occurring with low frequency (1.9% for K141N S -P203Q S , 4.7% for S98T S1, 7.5% for S210R S ) in non-HCC patients.Strong correlations are observed for P203Q S +S210R S (phi=0.83)and N40I S +K141N S (phi=0.56).S98T S1 corresponds to the nucleotide codon 3175-3177 of HBVgenome localized in the promoter of the middle S-protein.In in-vitro experiments, its presence determines a 3.71 foldincrease in HBsAg-levels released in supernatants (S98T: 127.47[sd±53.45]IU/ml;WT: 34.40[sd±13.28]IU/ml,P = 0.00016).An opposite scenario is observed for P203Q S +S210R S , localized in the membrane-embedded C-terminal domain critical for HBsAg-secretion.This couple of mutations drastically decreases supernatant HBsAg-levels compared to P203Q and S210R alone, and to wild-type (P203Q+S210R: 9.42[sd±1.35]IU/ml;P203Q: 26.85[sd±13.01]IU/ml;S210R: 25.95[sd±8.82]IU/ml;WT: 34.40[sd:±13.28]IU/ml,P < 0.01).P203Q+S210R also decrease the ratio of supernatant to lysate HBsAg compared to wild-type (0.61 for P203Q+S210R versus 1.20 for wild-type), supporting their ability in inducing HBsAg intracellular-retention.Similarly, K141N determines a 52%-reduction of supernatant HBsAglevels compared to wild-type (K141N: 13.43[sd±9.68]IU/ml;WT: 28.25[sd±13.12]IU/ml.This reduction is greater when K141N is co-present with N40I (K141N+N40I: 4.67[sd±2.31]IU/ml,P = 0.012).K141N introduces a new N-linked glycosylation-site, while N40I resides in the cytosolic-loop involved in HBsAg-secretion.Conclusions: Key genetic-elements in pre-S1/pre-S2/S-gene correlate with HCC by inducing intracellular HBsAg-retention and/or by potentially altering the production of mRNAs for S-gene.Their detection may help identifying patients at higher HCC-risk.

Evolutionary analysis of pre S/S mutations in HBeAg-negative chronic hepatitis B with HBsAg <100 IU/ml

Evolutionary Analysis of Pre-S/S Mutations in HBeAg-Negative Chronic Hepatitis B with HBsAg < 100 IU/ml

[Relationship between the quantitative results of HBV DNA and HBV markers (HBV M) in population with low-level HBsAg].

Mutations in hepatitis B virus DNA from patients with coexisting HBsAg and anti-HBs.

Host immunity and HBV S gene mutation in HBsAg-negative HBV-infected patients

Gene Heterogeneity of Hepatitis B Virus Isolates from Patients with Severe Hepatitis B.

Analysis of clinical characteristics and S gene sequences in chronic asymptomatic HBV carriers with low-level HBsAg

Detection of pre-S/S gene mutants in chronic hepatitis B carriers with concurrent hepatitis B surface antibody and hepatitis B surface antigen

432 TRANSFER OF HEPATITIS B SURFACE MARKERS AND HBVDNA FROM HEPATITIS B SURFACE ANTIGEN POSITIVE MOTHERS TO THEIR OFFSPRING

Sequence analysis of the Pre-S gene in chronic asymptomatic HBV carriers with low-level HBsAg

HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients

Evolutionary tendency of chronic severe hepatitis B-related mutations in mother-to-child transmission of hepatitis B virus

Pre-S1 Mutations as Indicated by Serum Pre-S1 Antigen Negative is Associated with an Increased Risk of Hepatocellular Carcinoma in Chronic B Patients

Hepatitis B Virus Pres/s Gene Mutations and Their Clinical Implications

Prevalence of S gene mutations within the major hydrophilic region of hepatitis B virus in patients in Dongguan, southern China

A study on sequence variations in preS/S regions of hepatitis B virus in occult infective patients

Immune-Escape Mutations Are Prevalent among Patients with a Coexistence of HBsAg and Anti-HBs in a Tertiary Liver Center in the United States

Study on the serology anomaly pattern of HBsAg and HBsAb positive at the same time of patients with HBV infection

Compartmentalized Evolution of Hepatitis B Virus Contributes Differently to the Prognosis of Hepatocellular Carcinoma.

Whole genome HBV deletion profiles and the accumulation of preS deletion mutant during antiviral treatment

Viral quasi-species evolution during hepatitis Be antigen seroconversion